Free Newsletter
First gene therapy for eye disease may offer a cure
Robin Ali, a professor of human molecular genetics at University College London, is leading the world's first human trial of a gene therapy for an eye condition. A total of 12 patients with Leber's Congenital Amaurocis are being treated in the trial. Their photoreceptor cells misfunction due to a faulty RPE65 gene. That is an extremely rare condition, but investigators say that if this trial works they'll be able to use a similar approach to treating about 100 single-gene sight disorders involving far larger numbers of patients. There are now a number of gene therapy studies which are moving from the lab into the clinic. That's a critical milestone for a field that has been regularly plagued by safety concerns. Now Ali and other researchers say they're on their way to putting those old fears into the past as they look forward to new therapies that offer cures.
- here's the report on the project from Time
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: